A Phase 2,Multicenter,Open-Label Study to Investigate the Efficacy, Safety and Pharmacokinetics of Ritonavir-boosted Danoprevir in Combination With Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis GT1
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Danoprevir (Primary) ; Peginterferon alfa-2a; Ribavirin; Ritonavir
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Ascletis
- 29 Jun 2017 Status changed from active, no longer recruiting to completed.
- 19 Jan 2017 New trial record